ASCO-GI – Astellas makes a case for its Vyloy triplet
Data from the Ilustro trial support the initiation of the phase 3 Lucerna study.
ASCO-GI – Jazz sees a new Ziihera Herizon
But Tevimbra’s role looks shaky as adverse events loom.
SABCS 2025 – Ember-3 brings no all-comers solace
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
SABCS 2025 – Carrick sees a way forward in CDK7
The group will start a pivotal trial of samuraciclib following promising second-line results.
SABCS 2025 – Gilead hasn’t given up on its Ascent
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
SABCS 2025 – Roche mounts its early breast cancer challenge
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
SABCS 2025 – pumitamig replicates breast cancer findings
Global phase 2 data in TNBC look similar to earlier results in China.
ASH 2025 – Lilly claims Jaypirca is best
Studies presented at ASH show this to be true only up to a point.
ASH 2025 – Regeneron’s Lynozyfic shows front-line promise
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
